Identification

Name
Cyclobenzaprine
Accession Number
DB00924  (APRD00213)
Type
Small Molecule
Groups
Approved
Description

Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond.

Structure
Thumb
Synonyms
  • (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
  • Ciclobenzaprina
  • Cyclobenzaprine
  • Cyclobenzaprinum
  • N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
  • N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External IDs
TNX-102
Product Ingredients
IngredientUNIICASInChI Key
Cyclobenzaprine Hydrochloride0VE05JYS2P6202-23-9VXEAYBOGHINOKW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmrixCapsule, extended release15 mg/1OralCephalon, Inc.2007-10-02Not applicableUs
AmrixCapsule, extended release15 mg/1OralStat Rx USA2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralA-S Medication Solutions2007-10-02Not applicableUs50090 110120180907 15195 4appjp
AmrixCapsule, extended release30 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-10-012015-12-31Us
AmrixCapsule, extended release30 mg/1OralCephalon, Inc.2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralStat Rx USA2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-01-03Not applicableUs
AmrixCapsule, extended release30 mg/1OralRebel Distributors2007-10-01Not applicableUs63459 0701 60 nlmimage10 602d3019
AmrixCapsule, extended release15 mg/1OralA-S Medication Solutions2007-10-01Not applicableUs54569 606420180907 15195 1kqht07
AmrixCapsule, extended release15 mg/1OralRebel Distributors2007-10-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cyclobenzaprine - Tab 10mgTablet10 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
Apo-cyclobenzaprineTablet10 mgOralApotex Corporation1995-12-31Not applicableCanada
Auro-cyclobenzaprineTablet10 mgOralAuro Pharma Inc2011-06-15Not applicableCanada
Ava-cyclobenzaprineTablet10 mgOralAvanstra Inc2011-10-112014-08-21Canada
Comfort Pac With CyclobenzaprineKit10 mg/1Pd Rx Pharmaceuticals, Inc.2013-07-15Not applicableUs
CyclobenzaprineTablet, film coated5 mg/1OralDirectrx2016-12-16Not applicableUs
CyclobenzaprineTablet, film coated7.5 mg/1OralCitron Pharma LLC2016-10-18Not applicableUs
Cyclobenzaprine HClTablet, film coated5 mg/1OralOxford Pharmaceuticals, Llc2018-01-25Not applicableUs
Cyclobenzaprine HClTablet, film coated10 mg/1OralOxford Pharmaceuticals, Llc2018-01-25Not applicableUs
Cyclobenzaprine HydrochlorideTablet10 mg/1OralCamber Pharmaceuticals2012-04-02Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cyclo/Gaba 10/300 PackCyclobenzaprine Hydrochloride (10 mg/1) + Gabapentin (300 mg/1)KitOralTmig, Inc.2011-01-29Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cyclo/MagCyclobenzaprine Hydrochloride (1 g/1g) + Magnesium oxide (1 g/1g)KitLiving Well Pharmacy, Inc.2010-03-03Not applicableUs
Cyclo/Mag 10mg/200mgCyclobenzaprine Hydrochloride (1 g/1g) + Magnesium oxide (1 g/1g)KitLiving Well Pharmacy, Inc.2010-02-17Not applicableUs
Cyclobenzaprine HydrochlorideCyclobenzaprine Hydrochloride (10 mg/1)Capsule, film coated, extended releaseOralSterling Knight Pharmaceuticals, Llc2016-10-31Not applicableUs
CyclobenzaprinePaxCyclobenzaprine Hydrochloride (10 mg/1) + Capsaicin (0.0375 g/100g) + Menthol (5 1/100g)KitSolubiomix2015-09-052016-03-04Us
CyclopheneCyclobenzaprine Hydrochloride (5.6 g/5.6g)KitCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
FlexePaxCyclobenzaprine Hydrochloride (10 mg/1) + Capsaicin (0.0375 g/100g) + Menthol (5 1/100g)KitBasiem2015-08-272016-03-04Us
Gapeam BudibacCyclobenzaprine Hydrochloride (1 g/1g) + Amantadine hydrochloride (1 g/1g) + Baclofen (1 g/1g) + Bupivacaine hydrochloride (1 g/1g) + Diclofenac sodium (1 g/1g) + Gabapentin (1 g/1g) + Pentoxifylline (1 g/1g)KitTopicalAlvix Laboratories2014-12-052018-03-08Us
TabradolCyclobenzaprine Hydrochloride (0.25 g/0.25g)KitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
TabradolCyclobenzaprine Hydrochloride (0.28 g/0.28g)KitOralFusion Pharmaceuticals LLC2009-09-17Not applicableUs
Therabenzaprine-60Cyclobenzaprine Hydrochloride (10 mg/1) + gamma-Aminobutyric acid (100 mg/1)KitPhysician Therapeutics Llc2011-05-15Not applicableUs
International/Other Brands
Flexeril (Janssen) / Flexiban (SIT)
Categories
UNII
69O5WQQ5TI
CAS number
303-53-7
Weight
Average: 275.3874
Monoisotopic: 275.167399677
Chemical Formula
C20H21N
InChI Key
JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Associated Conditions
Pharmacodynamics

Cyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.

Mechanism of action

Like other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Slowly but well absorbed after oral administration

Volume of distribution
Not Available
Protein binding

Very high (93%)

Metabolism

Extensively metabolized (gastrointestinal and hepatic).

Route of elimination

Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.

Half life

18 hours (range 8-37 hours)

Clearance
  • 0.7 L/min
Toxicity

Oral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of Cyclobenzaprine can be decreased when combined with (R)-warfarin.
(S)-WarfarinThe metabolism of Cyclobenzaprine can be decreased when combined with (S)-Warfarin.
2,4-thiazolidinedioneCyclobenzaprine may decrease the hypoglycemic activities of 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Cyclobenzaprine.
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with 3,4-Methylenedioxyamphetamine.
3,5-diiodothyropropionic acidThe metabolism of Cyclobenzaprine can be decreased when combined with 3,5-diiodothyropropionic acid.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Cyclobenzaprine.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Villani, F.J.; US. Patent 3,409,640; November 5,1968; assigned to Schering Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015060
KEGG Compound
C06931
PubChem Compound
2895
PubChem Substance
46508313
ChemSpider
2792
BindingDB
112774
ChEBI
3996
ChEMBL
CHEMBL669
Therapeutic Targets Database
DAP000891
PharmGKB
PA449160
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Cyclobenzaprine
ATC Codes
M03BX08 — Cyclobenzaprine
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (230 KB)
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentDriving Impaired1
1CompletedTreatmentHealthy Adults3
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentCervical Strain1
2TerminatedSupportive CarePain NOS / Sleep Initiation and Maintenance Disorders1
3CompletedTreatmentBack Pain / Cervical Pain / Spasms1
3CompletedTreatmentFibromyalgia, Primary1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
3Not Yet RecruitingTreatmentPain, Acute1
3Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
3TerminatedPreventionChronic Migraine1
3TerminatedTreatmentFibromyalgia, Primary1
3TerminatedTreatmentPost Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentAcute Low Back Pain1
4CompletedTreatmentPain NOS / Spasms1
4Unknown StatusTreatmentFibromyalgia / Pain NOS / Sleep / Tiredness1
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentTemporomandibular Disorders1
Not AvailableUnknown StatusTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Anesta ag
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Orit laboratories llc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Mcneil pediatrics
Packagers
  • 4uOrtho LLC
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Blenheim Pharmacal
  • Breckenridge Pharmaceuticals
  • Brighton Pharmaceuticals
  • Bryant Ranch Prepack
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Cephalon Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • ECR Pharmaceuticals
  • Endo Pharmaceuticals Inc.
  • Eurand Pharmaceuticals Inc.
  • Fusion Pharmaceuticals LLC
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • McNeil Laboratories
  • Medisca Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Neighborcare Repackaging Inc.
  • Nucare Pharmaceuticals Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stat Scripts LLC
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Victory Pharma
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
Kit10 mg/1
KitOral
Kit
Capsule, film coated, extended releaseOral10 mg/1
Capsule, film coated, extended releaseOral5 mg/1
TabletOral10 mg/1
TabletOral10 mg/10mg
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, coatedOral10 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Kit5.6 g/5.6g
Tablet, film coatedOral7.5 mg/1
KitTopical
TabletOral10 mg
KitOral0.25 g/0.25g
KitOral0.28 g/0.28g
Prices
Unit descriptionCostUnit
Cyclobenzaprine hcl crystal273.88USD g
Cyclobenzaprine hcl powder35.84USD g
Fexmid 7.5 mg tablet4.18USD tablet
Flexeril 5 mg tablet2.04USD tablet
Flexeril 10 mg tablet1.74USD tablet
Cyclobenzaprine HCl 5 mg tablet1.71USD tablet
Cyclobenzaprine 5 mg tablet1.64USD tablet
Cyclobenzaprine HCl 10 mg tablet0.47USD tablet
Cyclobenzaprine 10 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7544372No2009-06-092023-11-14Us
US7829121No2010-11-092023-11-14Us
US7820203No2010-10-262023-11-14Us
US7790199No2010-09-072023-11-14Us
US7387793No2008-06-172025-02-26Us
US9399025No2016-07-262023-11-14Us
US9375410No2016-06-282023-11-14Us
US8877245No2014-11-042023-11-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)173-177Not Available
water solubilityFreely SolubleNot Available
logP5.2Not Available
pKa8.47Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00689 mg/mLALOGPS
logP4.73ALOGPS
logP4.61ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.62 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organic tricyclic compound (CHEBI:3996)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911]
  2. Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996 Sep 5;311(1):29-35. [PubMed:8884233]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Cyclobenzaprine FDA label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Drug created on June 13, 2005 07:24 / Updated on November 21, 2018 07:14